Publications by authors named "Pablo Colorado"

Claim this Profile
L
Location, size, and risk factors of incident covert brain infarcts in patients with acute non-cardioembolic ischemic stroke: PACIFIC-STROKE trial.
Robert G Hart, Eric E Smith, Angela Wang, Hardi Mundl, Pablo Colorado

Eur Stroke J· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual versus single antiplatelet therapy in patients with non-cardioembolic acute ischemic stroke and baseline MRI.
Gian Marco De Marchis, Anna Toebak, Tolga Dittrich, Dimitrios Vlachos, Angela Wang, Pablo Colorado

Eur Stroke J· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial.
James E Udelson, Steven R Goldsmith, Daniel Burkhoff, Pablo Colorado, Wilfried Dinh

Eur J Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemorrhagic Infarction Does Not Worsen Functional Outcomes in Noncardioembolic Ischemic Stroke: Secondary Analysis From PACIFIC-STROKE.
Chih-Hao Chen, Ashkan Shoamanesh, Pablo Colorado, Feryal Saad, Robin Lemmens

Stroke· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebral microbleeds and asundexian in non-cardioembolic ischemic stroke: Secondary analyses of the PACIFIC-STROKE randomized trial.
Pargol Balali, Robert G Hart, Eric E Smith, Feryal Saad, Pablo Colorado

Int J Stroke· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemorrhagic Transformation in Noncardioembolic Acute Ischemic Stroke: MRI Analysis From PACIFIC-STROKE.
Chih-Hao Chen, Ashkan Shoamanesh, Pablo Colorado, Feryal Saad, Robin Lemmens

Stroke· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.
Eric E Smith, Ashkan Shoamanesh, Lizhen Xu, Laura Heenan, Feryal Saad, Pablo Colorado

Stroke· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
Ashkan Shoamanesh, Hardi Mundl, Eric E Smith, Jaime Masjuan, Ivan Milanov, Pablo Colorado

Lancet· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial.
Steven R Goldsmith, Daniel Burkhoff, Finn Gustafsson, Adriaan Voors, Faiez Zannad, Pablo Colorado

J Card Fail· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications : Bamberg, Germany. 23-25 June, 2017.
G. Todd Milne, , Peter Sandner, Kathleen A. Lincoln, Paul C. Harrison, Pablo Colorado

BMC Pharmacol Toxicol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Marius M Hoeper, Gérald Simonneau, Paul A Corris, Hossein-Ardeschir Ghofrani, James R Klinger, Pablo Colorado

Eur Respir J· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
Michael Halank, Marius M Hoeper, Hossein-Ardeschir Ghofrani, F Joachim Meyer, Gerd Stähler, Pablo Colorado

Respir Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Gérald Simonneau, Andrea M D'Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Pavel Jansa, Pablo Colorado

Lancet Respir Med· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
Gérald Simonneau, Andrea M D'Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M Hoeper, Pablo Colorado

Eur Respir J· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor.
Pia Nyberg, Liang Xie, Hikaru Sugimoto, Pablo Colorado, Malin Sund

Exp Cell Res· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver abscess and diarrhea as initial manifestations of ulcerative colitis: case report and review of the literature.
Jungsik Song, Michelle Swekla, Pablo Colorado, Rajasekhar Reddy, Stephen Hoffmann

Dig Dis Sci· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis